Nanobiotix is transforming into a capital-light oncology platform focused on milestone and royalty revenues, centered on its JNJ-1900 program now led by Johnson & Johnson. JNJ-1900 aims to enhance radiotherapy across multiple solid tumors, with a potential $2.6 billion milestone structure and double-digit royalties. Recent financing and a planned equity raise in May 2026 extend Nanobiotix's cash runway through 2029, transferring much clinical and operational risk to J&J. While speculative, Nanobiotix offers upside if its radiotherapy platform gains broad adoption but faces risks including clinical trial outcomes, operational challenges, and dilution from fundraising.
Smallest AI, a San Francisco-based AI research lab, has named Siddharth Sharma as President of Banking, Financial Services, and Insurance (BFSI) in India. Sharma will lead revenue and partnerships, focusing on voice AI solutions tailored for Indian b...
NVIDIA and Meta announced an expanded collaboration to improve the Muse family of AI models, aiming to boost performance and efficiency for AI agents. Meta will increase deployment of NVIDIA's Vera Rubin and Vera CPUs, along with Spectrum-X Ethernet ...
U.S. spot Bitcoin ETFs experienced a net inflow of $110.34 million on October 26, 2026, reversing two days of withdrawals totaling $137.94 million. This inflow was driven entirely by BlackRock's IBIT, which attracted the full amount. The total tradin...
U.S. spot Ethereum ETFs experienced net outflows of $88.58 million on October 26, 2026, reversing a brief period of inflows. BlackRock's ETHA fund led the withdrawals with $104.71 million, while Fidelity's FETH was the only fund to see inflows, attra...
Oil prices fell on Tuesday following diplomatic talks in Tehran involving Saudi Arabia, Turkey, Pakistan, and Iran aimed at reducing tensions in the Middle East. These discussions have raised hopes for de-escalation in the ongoing U.S.-Iran conflict,...
